This analysis examines the historical and forecast performance for Sepracor in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Sepracor's performance against key rivals in the ethical pharmaceutical sector See how the company has achieved profitability following the launches of Xopenex HFA and Lunesta in 2005 Evaluate Sepracor's long-term growth prospects in the context of the expected 2010 patent expiry of its first product, Xopenex Inhalation Solution.